drugset / Trial / NCT05775094

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

NCT05775094

Phase 1 Active not recruiting 10 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in postmenopausal people with multiple myeloma (MM).

Timeline

Start
2023-03-07
Primary completion
2027-03
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Romosozumab Monoclonal antibody 210 mg Subcutaneous